Biologic agents and approaches in the management of patients with lymphoma. A critical appraisal.
There are many new approaches to cancer treatment emerging as a result of improvements in our understanding of tumor biology and the host response to cancer. At this time, none of these new approaches are sufficiently active or well developed to replace or improve upon standard combination chemotherapy in the management of patients with lymphoma.
Longo
D L
DL
Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001685:Biological Factors / Q000627:therapeutic use*; D003115:Colony-Stimulating Factors / Q000627:therapeutic use; D006801:Humans; D016219:Immunotherapy, Adoptive; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D008223:Lymphoma / Q000628:therapy*
D000911:Antibodies, Monoclonal; D001685:Biological Factors; D003115:Colony-Stimulating Factors; D007376:Interleukin-2; D007372:Interferons